Bristol-Myers buys rights to acquire fibrosis drug developer: Reuters
Drugmaker Bristol-Myers Squibb said it bought rights to a mid-stage fibrosis drug and its privately held developer for up to $1.25 billion, boosting its pipeline for drugs that treat tissue scarring, Reuters News reported.
31 August 2015•1 min read
